<DOC>
	<DOCNO>NCT02516202</DOCNO>
	<brief_summary>This new application Menopause Strategies : Finding Lasting Answers Symptoms Health ( MsFLASH ) Clinical Trials network . Here propose conduct large multicenter trial compare two common treatment , vaginal hormone tablet over-the-counter gel , placebo evaluate effect bothersome vaginal symptom sexual function , create biorepository specimen future translational , mechanistic research etiology vaginal symptom .</brief_summary>
	<brief_title>The Vaginal Health Trial</brief_title>
	<detailed_description>The Menopause Strategies : Finding Lasting Answers Symptoms Health ( MsFLASH ) Clinical Trials network establish 2009 . By end 2014 , network complete 4 clinical trial test 7 intervention approximately 1000 woman age 40-62 vasomotor ( VMS ) menopause symptom . The current trial evaluate relatively understudied area menopause - vaginal health sexual function . This 3-arm , randomize , control , double-blind , clinical trial among postmenopausal woman age 45-70 . Our primary aim evaluate effectiveness ultra-low dose vaginal estradiol ( Vagifem 10 mcg ) , non-hormonal hydrophilic non-prescriptive vaginal gel ( Replens ) placebo reduce Most Bothersome vaginal Symptom ( MBS ) . Secondary aim include evaluation composite score vaginal symptom ( dryness , itching , irritation soreness ) , sexual function , quality life genitourinary atrophy . We also create biorepository vaginal blood specimen . In subset woman , examine whether treatment response relate : ) post-menopausal vaginal microbiome ; b ) vaginal mucosal inflammation ; c ) reproductive hormone profile . The in-depth focus mechanism associate postmenopausal vaginal symptom use state art microbiologic technique longitudinally collect biologic specimen guide future translational study .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Vaginal Discharge</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Psyllium</mesh_term>
	<mesh_term>Calcium polycarbophil</mesh_term>
	<criteria>Inclusion Criteria Females age 4570 year 2 year since last natural menstrual period , surgical menopause ( bilateral oophorectomy ) At least 1 vaginal symptom ( inside outside vagina ) report following list , experience past 30 day moderate severe : Dryness least week Itching least week Irritation least week Soreness/Pain least week Pain associate sexual activity least Signed informed consent Exclusion Criteria Current unexplained abnormal genital bleeding ( unevaluated bleeding since menopause ) Currently pregnant , attempt pregnancy breast feed Current acute vaginal infection ( indicated wet mount V1 ) Pelvic vaginal surgery prior 60 day Antibiotic use past 30 day Women age 55 endometrial ablation Women age 55 hysterectomy least one ovary Current cancer treatment ( exception basal squamous skin cell cancer ) Current past thromboembolic disease ( pulmonary embolus deep vein thrombosis , include thrombophlebitis ) , myocardial infarction stroke Current severe liver disease Current past breast endometrial cancer precancer Blood clot disorder ( e.g. , Factor V Leiden , prothrombin mutation , protein C , protein antithrombin deficiency ) Porphyria Current past lichen sclerosus lichen planus History adverse reaction vaginal estrogen Replens Use systemic reproductive hormone ( hormonal contraception , postmenopausal hormone therapy , SERMS ) past 2 month Use hormonal contraception past year Use type vaginal estrogen product ( however interested woman allow join study abstain use month precede enrollment ) Use type vaginal moisturizer , douche , vaginal prebiotic probiotic , soap vagina past month ( however interested woman allow join study abstain use month precede enrollment ) Unwilling abstain use nonstudy vaginal moisturizer , vaginal estrogen , douche , soap vagina throughout trial Unable follow instruction , complete questionnaire , physically unable place product vagina Current participation another drug trial intervention study Chronic vulvovaginal symptom 5 year menopause ( defined vaginal vulvar condition require 4 visit health care provider give year )</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>